Details for Patent: 9,616,097

Which drugs does patent 9,616,097 protect, and when does it expire?

Patent 9,616,097 protects TRULANCE and is included in one NDA.

This patent has twenty-three patent family members in eight countries.

Summary for Patent: 9,616,097

Title:	Formulations of guanylate cyclase C agonists and methods of use
Abstract:	The invention provides low-dose formulations of guanylate cyclase-C ("GCC") agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.
Inventor(s):	Comiskey; Stephen (Doylestown, PA), Feng; Rong (Langhorne, PA), Foss; John (Doylestown, PA), Shailubhai; Kunwar (Audubon, PA)
Assignee:	SYNERGY PHARMACEUTICALS, INC. (New York, NY)
Application Number:	13/421,769
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,616,097
Patent Claim Types: see list of patent claims	Composition; Formulation; Dosage form;

Drugs Protected by US Patent 9,616,097

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Salix	TRULANCE	plecanatide	TABLET;ORAL	208745-001	Jan 19, 2017		RX	Yes	Yes			Y

International Family Members for US Patent 9,616,097

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2011302006
Australia	2013232306
Australia	2016216716
Australia	2018286626